TABLE 4.
Sensitivity Analyses Showing the Association Between β Blocker Exposure and the Risks of Neonatal Hypoglycemia and Neonatal Bradycardia
| Neonatal Hypogylcemia, OR (95% CI) | Neonatal Bradycardia, OR (95% CI) | |
|---|---|---|
| Reference methyldopaa | ||
| Unadjusted | 1.57 (1.34–1.83) | 1.28 (1–1.63) |
| PS-matched | 1.67 (1.39–2.01) | 1.21 (0.91–1.6) |
| hd-PS adjustment | ||
| Unadjusted | 3.76 (3.42–4.13) | 3.08 (2.64–3.6) |
| PS-matched | 1.44 (1.28–1.63) | 1.09 (0.90–1.32) |
| Restricted: patients with diabetesb | ||
| Unadjusted | 2.83 (2.39–3.36) | N/A |
| PS-matched | 1.50 (1.22–1.84) | N/A |
| Restricted: term deliveries | ||
| Unadjusted | 3.10 (2.64–3.65) | 2.07 (1.4–3.04) |
| PS-matched | 1.69 (1.38–2.06) | 1.35 (0.85–2.14) |
| Excluding patients from reference group with β blocker exposure | ||
| Unadjusted | 3.77 (3.43–4.15) | 3.10 (2.65–3.61) |
| PS-matched | 1.69 (1.51–1.90) | 1.27 (1.06–1.53) |
| Excluded neonates with preterm delivery, small for gestational age, low birth weight, or intrauterine hypoxemia/birth asphyxia | ||
| Unadjusted | 2.98 (2.50–3.55) | 2.05 (1.35–3.12) |
| PS-matched | 1.53 (1.24–1.90) | 1.61 (0.96–2.71) |
| Two codes in the infant record | ||
| Unadjusted | 3.73 (3.2–4.34) | 3.29 (2.39–4.53) |
| PS-matched | 1.70 (1.41–2.06) | 1.34 (0.92–1.97) |
| Codes from inpatient claims only | ||
| Unadjusted | 3.66 (3.29–4.06) | 3.21 (2.72–3.80) |
| PS-matched | 1.79 (1.57–2.04) | 1.30 (1.07–1.59) |
| Codes in the infant or maternal record | ||
| Unadjusted | 3.76 (3.44–4.12) | 3.00 (2.58–3.49) |
| PS-matched | 1.67 (1.49–1.86) | 1.25 (1.05–1.5) |
N/A, not applicable.
a
1:1 (given similar numbers in unmatched cohorts in both groups).
b
Restricted: patient with preexisting or gestational diabetes.